Please provide your email address to receive an email when new articles are posted on . The FDA has approved a self-administered injection of the leukocyte growth factor tbo-filgrastim for patients ...

Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information ...

JERUSALEM — Teva Pharmaceutical today announced that the Food and Drug Administration has approved Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the ...

The pediatric approval was supported by evidence from studies in adults with additional safety and pharmacokinetics data from a single-arm trial of 50 pediatric patients with solid tumors treated with ...

The FDA approves Teva Pharmaceutical Industries' (NYSE:TEVA) Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. This will enable physicians to prescribe the product ...

New Granix Syringes Approved for Self-Administration Teva Oncology announced the launch of a new single-use pre-filled syringe for self-administration for Granix (tbo-filgrastim). Teva Oncology ...

Teva Pharmaceuticals announced that FDA approved Granix injection for self-administration in patients. Teva Pharmaceuticals announced on Dec. 23, 2014 that it received FDA approval of Granix ...

Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information ...